 |
12 Diseases |  |
144 Trials |
|
144 Trials |  |
4081 News |  |
| «12...30313233343536373839404142» |
- |||| Victoza (liraglutide) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk, semaglutide SC once-daily (NN9536) / Novo Nordisk
Clinical: Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes (clinicaltrials.gov) - Sep 24, 2015
P2, N=704, Recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting
- ||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk, semaglutide SC once-daily (NN9536) / Novo Nordisk
Clinical: Comparing Semaglutide Administered Subcutaneously Once Daily to Semaglutide Administered Subcutaneously Once Weekly (clinicaltrials.gov) - Sep 23, 2015
P1, N=114, Not yet recruiting, Sponsor: Novo Nordisk A/S
- ||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: SUSTAIN 4: Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes (clinicaltrials.gov) - Sep 10, 2015
P3, N=1089, Completed, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: SUSTAIN™ 3: Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes (clinicaltrials.gov) - Jul 16, 2015
P3, N=813, Completed, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Victoza (liraglutide) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk, semaglutide SC once-daily (NN9536) / Novo Nordisk
Clinical: Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes (clinicaltrials.gov) - Jun 3, 2015
P2, N=704, Not yet recruiting, Sponsor: Novo Nordisk A/S
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: A Trial Investigating the Effect of Semaglutide on Hypoglycaemic Counterregulation Compared to Placebo in Subjects With Type 2 Diabetes (clinicaltrials.gov) - May 26, 2015
P1, N=38, Completed, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: A Trial Investigating the Effects of Semaglutide on ß-cell Function in Subjects With Type 2 Diabetes (clinicaltrials.gov) - May 13, 2015
P1, N=87, Completed, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: SUSTAIN™1: Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes (clinicaltrials.gov) - May 13, 2015
P3, N=387, Completed, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: Investigating the Influence of Semaglutide on the Pharmacokinetics of Single Doses of Atorvastatin and Digoxin in Healthy Subjects (clinicaltrials.gov) - Apr 13, 2015
P1, N=31, Completed, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Combination therapy: SUSTAIN (clinicaltrials.gov) - Mar 31, 2015
P3, N=397, Active, not recruiting, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Monotherapy: SUSTAIN: A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 Diabetes (clinicaltrials.gov) - Mar 10, 2015
P3, N=306, Active, not recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2016 --> Nov 2015
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: Investigating the Influence of Semaglutide on the Pharmacokinetics of Single Doses of Atorvastatin and Digoxin in Healthy Subjects (clinicaltrials.gov) - Feb 5, 2015
P1, N=28, Active, not recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2016 --> Nov 2015 Trial primary completion date: Jul 2015 --> Apr 2015
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo (clinicaltrials.gov) - Jan 26, 2015
P1, N=30, Completed, Sponsor: Novo Nordisk A/S
Trial primary completion date: Jul 2015 --> Apr 2015 Active, not recruiting --> Completed
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Combination therapy, Monotherapy: A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes (clinicaltrials.gov) - Jan 7, 2015
P3, N=595, Active, not recruiting, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: SUSTAIN 4: Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes (clinicaltrials.gov) - Jan 6, 2015
P3, N=1047, Active, not recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: A Trial Investigating the Effects of Semaglutide on ß-cell Function in Subjects With Type 2 Diabetes (clinicaltrials.gov) - Dec 19, 2014
P1, N=82, Active, not recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial completion: Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes (clinicaltrials.gov) - Dec 17, 2014
P2, N=632, Completed, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Combination therapy: SUSTAIN (clinicaltrials.gov) - Dec 7, 2014
P3, N=390, Recruiting, Sponsor: Novo Nordisk A/S
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: Investigating the Influence of Semaglutide on the Pharmacokinetics of Single Doses of Atorvastatin and Digoxin in Healthy Subjects (clinicaltrials.gov) - Dec 5, 2014
P1, N=28, Active, not recruiting, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo (clinicaltrials.gov) - Nov 3, 2014
P1, N=30, Active, not recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Trial primary completion date: May 2015 --> Jan 2015
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: A Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian Subjects (clinicaltrials.gov) - Oct 23, 2014
P1, N=44, Completed, Sponsor: Novo Nordisk A/S
Trial primary completion date: May 2015 --> Jan 2015 Active, not recruiting --> Completed
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Monotherapy: SUSTAIN: A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 Diabetes (clinicaltrials.gov) - Oct 4, 2014
P3, N=306, Recruiting, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Monotherapy: SUSTAIN: A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 Diabetes (clinicaltrials.gov) - Oct 2, 2014
P3, N=306, Not yet recruiting, Sponsor: Novo Nordisk A/S
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: Investigating the Influence of Semaglutide on the Pharmacokinetics of Single Doses of Atorvastatin and Digoxin in Healthy Subjects (clinicaltrials.gov) - Sep 30, 2014
P1, N=28, Recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: A Trial Investigating the Effect of Semaglutide on Hypoglycaemic Counterregulation Compared to Placebo in Subjects With Type 2 Diabetes (clinicaltrials.gov) - Sep 28, 2014
P1, N=38, Active, not recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: Investigating the Influence of Semaglutide on the Pharmacokinetics of Single Doses of Atorvastatin and Digoxin in Healthy Subjects (clinicaltrials.gov) - Sep 19, 2014
P1, N=28, Not yet recruiting, Sponsor: Novo Nordisk A/S
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: A Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian Subjects (clinicaltrials.gov) - Sep 4, 2014
P1, N=44, Active, not recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Trial primary completion date: Feb 2015 --> Oct 2014
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: SUSTAIN™1: Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes (clinicaltrials.gov) - Aug 25, 2014
P3, N=390, Active, not recruiting, Sponsor: Novo Nordisk A/S
Trial primary completion date: Feb 2015 --> Oct 2014 Recruiting --> Active, not recruiting
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: A Trial Investigating the Effects of Semaglutide on ß-cell Function in Subjects With Type 2 Diabetes (clinicaltrials.gov) - Aug 15, 2014
P1, N=86, Recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: A Trial Investigating the Effects of Semaglutide on ß-cell Function in Subjects With Type 2 Diabetes (clinicaltrials.gov) - Aug 8, 2014
P1, N=86, Not yet recruiting, Sponsor: Novo Nordisk A/S
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: SUSTAIN™ 2: Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes (clinicaltrials.gov) - Aug 7, 2014
P3, N=1200, Active, not recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: SUSTAIN 4: Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes (clinicaltrials.gov) - Aug 6, 2014
P3, N=1047, Recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Combination therapy, Monotherapy: A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes (clinicaltrials.gov) - Aug 5, 2014
P3, N=595, Recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Combination therapy, Monotherapy: A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes (clinicaltrials.gov) - Aug 4, 2014
P3, N=595, Not yet recruiting, Sponsor: Novo Nordisk A/S
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo (clinicaltrials.gov) - Jul 4, 2014
P1, N=30, Active, not recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: A Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian Subjects (clinicaltrials.gov) - Jun 27, 2014
P1, N=44, Active, not recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: A Trial Investigating the Effect of Semaglutide on Hypoglycaemic Counterregulation Compared to Placebo in Subjects With Type 2 Diabetes (clinicaltrials.gov) - May 22, 2014
P1, N=38, Recruiting, Sponsor: Novo Nordisk A/S
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: A Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian Subjects (clinicaltrials.gov) - May 21, 2014
P1, N=44, Recruiting, Sponsor: Novo Nordisk A/S
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: SUSTAIN 4: Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes (clinicaltrials.gov) - Apr 23, 2014
P3, N=1047, Not yet recruiting, Sponsor: Novo Nordisk A/S
- Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment closed: Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes (clinicaltrials.gov) - Apr 23, 2014
P2, N=603, Active, not recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: SUSTAIN™ 3: Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes (clinicaltrials.gov) - Apr 22, 2014
P3, N=798, Active, not recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo (clinicaltrials.gov) - Mar 9, 2014
P1, N=30, Recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo (clinicaltrials.gov) - Mar 4, 2014
P1, N=30, Recruiting, Sponsor: Novo Nordisk A/S
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: SUSTAIN™1: Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes (clinicaltrials.gov) - Feb 3, 2014
P3, N=390, Recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: SUSTAIN™1: Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes (clinicaltrials.gov) - Feb 2, 2014
P3, N=390, Recruiting, Sponsor: Novo Nordisk A/S
- ||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: SUSTAIN™ 6: Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes (clinicaltrials.gov) - Dec 10, 2013
P3, N=3260, Active, not recruiting, Sponsor: Novo Nordisk
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: SUSTAIN™ 2: Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes (clinicaltrials.gov) - Dec 3, 2013
P3, N=1200, Recruiting, Sponsor: Novo Nordisk
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: SUSTAIN™ 2: Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes (clinicaltrials.gov) - Aug 26, 2013
P3, N=1200, Recruiting, Sponsor: Novo Nordisk
- | Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
New P2 trial: Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes (clinicaltrials.gov) - Aug 13, 2013
P2, N=603, Active, not recruiting, Sponsor: Novo Nordisk A/S
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: SUSTAIN™ 3: Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes (clinicaltrials.gov) - Jun 20, 2013
P3, N=798, Active, not recruiting, Sponsor: Novo Nordisk A/S